NCT04827316 Clinical Utility and Outcome Prediction of Cardiovascular Computed Tomography (PREDICT-CT)
| NCT ID | NCT04827316 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,200 participants |
| Start Date | 2017-06-01 |
| Primary Completion | 2031-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,200 participants in total. It began in 2017-06-01 with a primary completion date of 2031-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study the investigators retrospectively and prospectively collect information from enrolled subjects undergoing CCTA and evaluate the association of cardiac and non-cardiac imaging with laboratory markers and clinical data including outcome.
Eligibility Criteria
Inclusion Criteria: * Adult individual \>18 years * Undergoing clinically indicated CCTA * Signed informed consent or waiver Exclusion Criteria: * None
Contact & Investigator
Christoph Gräni, MD, PhD
PRINCIPAL INVESTIGATOR
Department of Cardiology, University Hospital Bern,
Frequently Asked Questions
Who can join the NCT04827316 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04827316 currently recruiting?
Yes, NCT04827316 is actively recruiting participants. Contact the research team at christoph.graeni@insel.ch for enrollment information.
Where is the NCT04827316 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT04827316 clinical trial?
NCT04827316 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Christoph Gräni, MD, PhD at Department of Cardiology, University Hospital Bern,. The trial plans to enroll 4,200 participants.